Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Galectin-3 binds selectively to the terminal, non-reducing end of β(1→4)-galactans, with overall affinity increasing with chain length.

Miller MC, Zheng Y, Zhou Y, Tai G, Mayo KH.

Glycobiology. 2018 Sep 11. doi: 10.1093/glycob/cwy085. [Epub ahead of print]

PMID:
30204870
2.

Galectins as Molecular Targets for Therapeutic Intervention.

Dings RPM, Miller MC, Griffin RJ, Mayo KH.

Int J Mol Sci. 2018 Mar 19;19(3). pii: E905. doi: 10.3390/ijms19030905. Review.

3.

Adhesion/growth-regulatory galectins tested in combination: evidence for formation of hybrids as heterodimers.

Miller MC, Ludwig AK, Wichapong K, Kaltner H, Kopitz J, Gabius HJ, Mayo KH.

Biochem J. 2018 Mar 15;475(5):1003-1018. doi: 10.1042/BCJ20170658.

PMID:
29321242
4.

Macromolecular assemblies of complex polysaccharides with galectin-3 and their synergistic effects on function.

Zhang T, Miller MC, Zheng Y, Zhang Z, Xue H, Zhao D, Su J, Mayo KH, Zhou Y, Tai G.

Biochem J. 2017 Nov 9;474(22):3849-3868. doi: 10.1042/BCJ20170143.

PMID:
28986508
5.

Chemokines from a Structural Perspective.

Miller MC, Mayo KH.

Int J Mol Sci. 2017 Oct 2;18(10). pii: E2088. doi: 10.3390/ijms18102088. Review.

6.

Novel polysaccharide binding to the N-terminal tail of galectin-3 is likely modulated by proline isomerization.

Miller MC, Zheng Y, Yan J, Zhou Y, Tai G, Mayo KH.

Glycobiology. 2017 Nov 1;27(11):1038-1051. doi: 10.1093/glycob/cwx071.

PMID:
28973299
7.

Intra- and intermolecular interactions of human galectin-3: assessment by full-assignment-based NMR.

Ippel H, Miller MC, Vértesy S, Zheng Y, Cañada FJ, Suylen D, Umemoto K, Romanò C, Hackeng T, Tai G, Leffler H, Kopitz J, André S, Kübler D, Jiménez-Barbero J, Oscarson S, Gabius HJ, Mayo KH.

Glycobiology. 2016 Aug;26(8):888-903. doi: 10.1093/glycob/cww021. Epub 2016 Feb 23.

8.

Binding of polysaccharides to human galectin-3 at a noncanonical site in its carbohydrate recognition domain.

Miller MC, Ippel H, Suylen D, Klyosov AA, Traber PG, Hackeng T, Mayo KH.

Glycobiology. 2016 Jan;26(1):88-99. doi: 10.1093/glycob/cwv073.

9.

Structural significance of galectin design: impairment of homodimer stability by linker insertion and partial reversion by ligand presence.

Vértesy S, Michalak M, Miller MC, Schnölzer M, André S, Kopitz J, Mayo KH, Gabius HJ.

Protein Eng Des Sel. 2015 Jul;28(7):199-210. doi: 10.1093/protein/gzv014. Epub 2015 Mar 21.

PMID:
25796447
10.

Defining the potential of aglycone modifications for affinity/selectivity enhancement against medically relevant lectins: synthesis, activity screening, and HSQC-based NMR analysis.

Rauthu SR, Shiao TC, André S, Miller MC, Madej É, Mayo KH, Gabius HJ, Roy R.

Chembiochem. 2015 Jan 2;16(1):126-39. doi: 10.1002/cbic.201402474. Epub 2014 Nov 18.

PMID:
25407851
11.

(1)H, (13)C, and (15)N backbone and side-chain chemical shift assignments for the 36 proline-containing, full length 29 kDa human chimera-type galectin-3.

Ippel H, Miller MC, Berbís MA, Suylen D, André S, Hackeng TM, Cañada FJ, Weber C, Gabius HJ, Jiménez-Barbero J, Mayo KH.

Biomol NMR Assign. 2015 Apr;9(1):59-63. doi: 10.1007/s12104-014-9545-3. Epub 2014 Feb 7.

12.

Pathways of introduction of the invasive aquatic plant Cabomba caroliniana.

McCracken A, Bainard JD, Miller MC, Husband BC.

Ecol Evol. 2013 Jun;3(6):1427-39. doi: 10.1002/ece3.530. Epub 2013 Apr 15.

13.

Lactose binding to human galectin-7 (p53-induced gene 1) induces long-range effects through the protein resulting in increased dimer stability and evidence for positive cooperativity.

Ermakova E, Miller MC, Nesmelova IV, López-Merino L, Berbís MA, Nesmelov Y, Tkachev YV, Lagartera L, Daragan VA, André S, Cañada FJ, Jiménez-Barbero J, Solís D, Gabius HJ, Mayo KH.

Glycobiology. 2013 May;23(5):508-23. doi: 10.1093/glycob/cwt005. Epub 2013 Jan 31.

14.

Structure-based optimization of angiostatic agent 6DBF7, an allosteric antagonist of galectin-1.

Dings RP, Kumar N, Miller MC, Loren M, Rangwala H, Hoye TR, Mayo KH.

J Pharmacol Exp Ther. 2013 Mar;344(3):589-99. doi: 10.1124/jpet.112.199646. Epub 2012 Dec 11.

15.

Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding.

Dings RP, Miller MC, Nesmelova I, Astorgues-Xerri L, Kumar N, Serova M, Chen X, Raymond E, Hoye TR, Mayo KH.

J Med Chem. 2012 Jun 14;55(11):5121-9. doi: 10.1021/jm300014q. Epub 2012 May 30.

16.

Structural features for α-galactomannan binding to galectin-1.

Miller MC, Klyosov AA, Mayo KH.

Glycobiology. 2012 Apr;22(4):543-51. doi: 10.1093/glycob/cwr173. Epub 2011 Dec 7.

17.

1H, 13C, and 15N backbone and side-chain chemical shift assignments for the 31 kDa human galectin-7 (p53-induced gene 1) homodimer, a pro-apoptotic lectin.

Nesmelova IV, Berbís MÁ, Miller MC, Cañada FJ, André S, Jiménez-Barbero J, Gabius HJ, Mayo KH.

Biomol NMR Assign. 2012 Oct;6(2):127-9. doi: 10.1007/s12104-011-9339-9. Epub 2011 Sep 7.

PMID:
21898049
18.

Structural aspects of binding of α-linked digalactosides to human galectin-1.

Miller MC, Ribeiro JP, Roldós V, Martín-Santamaría S, Cañada FJ, Nesmelova IA, André S, Pang M, Klyosov AA, Baum LG, Jiménez-Barbero J, Gabius HJ, Mayo KH.

Glycobiology. 2011 Dec;21(12):1627-41. doi: 10.1093/glycob/cwr083. Epub 2011 Jun 28.

19.

The alpha-galactomannan Davanat binds galectin-1 at a site different from the conventional galectin carbohydrate binding domain.

Miller MC, Klyosov A, Mayo KH.

Glycobiology. 2009 Sep;19(9):1034-45. doi: 10.1093/glycob/cwp084. Epub 2009 Jun 18.

20.

Using pulse field gradient NMR diffusion measurements to define molecular size distributions in glycan preparations.

Miller MC, Klyosov A, Platt D, Mayo KH.

Carbohydr Res. 2009 Jul 6;344(10):1205-12. doi: 10.1016/j.carres.2009.04.010. Epub 2009 Apr 17.

PMID:
19457477

Supplemental Content

Loading ...
Support Center